Deals In Depth: December 2012
Biogen and Isis teamed up in their third antisense deal. Baxter paid $4 billion for its partner, dialysis company Gambro. Biopharma financing was boosted by Amarin’s large debt offering and a couple $100 million-plus FOPOs. Volcano’s $445 million notes deal drove device fundraising to $604 million.